ID   KTC-2
AC   CVCL_6476
SY   KTC2
DR   cancercelllines; CVCL_6476
DR   Cosmic; 1239964
DR   Cosmic; 2054080
DR   Wikidata; Q54900621
RX   CelloPub=CLPUB00144;
RX   PubMed=12729473;
RX   PubMed=18713817;
RX   PubMed=23833040;
RX   PubMed=25675381;
RX   PubMed=30737244;
CC   Population: Japanese.
CC   Doubling time: 36 +- 3 hours (PubMed=12729473).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Glu490Ter (c.1468G>T); Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): PubMed=18713817; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8,12
ST   D16S539: 10,11
ST   D18S51: 16
ST   D21S11: 30
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 11
ST   D8S1179: 12
ST   FGA: 23
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   70Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 19
//
RX   CelloPub=CLPUB00144;
RA   Kurebayashi J., Tanaka K., Yamamoto Y., Okubo S., Sonoo H.;
RT   "Human epidermal growth factor receptor 1 and thrombospondin-1 in
RT   thyroid cancer.";
RL   (In book chapter) Trends in thyroid cancer research. Horizons in cancer research, Vol. 37; Milton C.A. (eds.); pp.89-116; Nova Science Publishers; Hauppauge; USA (2007).
//
RX   PubMed=12729473; DOI=10.1089/105072503321582042;
RA   Kurebayashi J., Otsuki T., Tanaka K., Yamamoto Y., Moriya T.,
RA   Sonoo H.;
RT   "Medroxyprogesterone acetate decreases secretion of interleukin-6 and
RT   parathyroid hormone-related protein in a new anaplastic thyroid cancer
RT   cell line, KTC-2.";
RL   Thyroid 13:249-258(2003).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25675381; DOI=10.1210/jc.2014-2764; PMCID=PMC4422887;
RA   von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J.,
RA   Tun H.W., Smallridge R.C., Copland J.A. 3rd;
RT   "Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals
RT   stearoyl CoA desaturase 1 as a novel therapeutic target.";
RL   J. Clin. Endocrinol. Metab. 100:E697-E709(2015).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//